ORLANDO, FLA.—In a dose-escalation study, a novel investigational bispecific antibody therapy called mosunetuzumab produced durable complete responses (CRs) in patients with refractory B-cell malignancies, including those who had failed previous chimeric antigen receptor (CAR) T-cell therapy. Although this is an early-phase study, response rates were high and sustained.
“The CRs appear to be durable,” reported Stephen J. Schuster, MD, the director of Lymphoma Translational